Last update at 2025-03-14T20:00:00Z
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
Wed 05 Mar 25, 11:36 AMAcadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
Tue 04 Mar 25, 09:09 AMACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Mon 03 Mar 25, 06:57 PMAcadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
Thu 27 Feb 25, 03:48 PMAcadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Wed 26 Feb 25, 10:25 PMIs the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock?
Thu 13 Feb 25, 01:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -213.44400M | -167.51900M | -280.97300M | -234.38300M | -243.93600M |
| Minority interest | - | - | - | - | - |
| Net income | -215.97500M | -167.87000M | -281.58400M | -235.25900M | -245.19200M |
| Selling general administrative | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 507.07M | 465.00M | 421.20M | 319.48M | 205.48M |
| Reconciled depreciation | 2.03M | 3.34M | 2.93M | 2.77M | 3.00M |
| Ebit | -225.62200M | -173.78300M | -289.51800M | -249.31100M | -250.44900M |
| Ebitda | -223.59600M | -170.43900M | -286.58600M | -246.54500M | -247.44400M |
| Depreciation and amortization | 2.03M | 3.34M | 2.93M | 2.77M | 3.00M |
| Non operating income net other | - | -2.32900M | -0.99700M | 1.00M | -1.84000M |
| Operating income | -223.59600M | -170.43900M | -286.58600M | -246.54500M | -247.44400M |
| Other operating expenses | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M |
| Interest expense | 6.61M | 6.26M | 8.54M | 14.93M | 0.00000M |
| Tax provision | 2.53M | 0.35M | 0.61M | 0.88M | 1.26M |
| Interest income | 6.61M | 0.59M | 6.61M | 11.16M | 5.35M |
| Net interest income | 6.61M | 0.59M | 6.61M | 11.16M | 5.35M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2.53M | 0.35M | 0.61M | 0.88M | 1.26M |
| Total revenue | 517.24M | 484.14M | 441.75M | 339.08M | 223.81M |
| Total operating expenses | 730.66M | 635.44M | 707.79M | 566.02M | 452.92M |
| Cost of revenue | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M |
| Total other income expense net | 10.15M | 2.92M | 5.61M | 12.16M | -1.84000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -215.97500M | -167.87000M | -281.58400M | -235.25900M | -245.19200M |
| Net income applicable to common shares | -215.97500M | -167.87000M | -281.58400M | -235.25900M | -245.19200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 748.96M | 587.81M | 700.12M | 782.62M | 783.18M |
| Intangible assets | 65.49M | - | - | 1.11M | 2.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | 39.09M | 21.40M | 23.89M | 25.69M | 18.61M |
| Total liab | 317.20M | 187.40M | 159.23M | 155.61M | 84.05M |
| Total stockholder equity | 431.75M | 400.41M | 540.89M | 627.01M | 699.13M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 225.74M | 103.58M | 80.89M | 92.39M | 64.17M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M |
| Retained earnings | -2430.83700M | -2369.55100M | -2153.57600M | -1985.70600M | -1704.12200M |
| Other liab | - | 9.07M | 7.03M | 5.18M | 2.86M |
| Good will | 0.00000M | - | - | - | - |
| Other assets | - | 11.08M | 15.98M | 54.73M | 5.34M |
| Cash | 188.66M | 114.85M | 147.44M | 326.03M | 189.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 254.25M | 125.63M | 96.07M | 105.97M | 74.83M |
| Current deferred revenue | 1.56M | - | - | - | - |
| Net debt | -131.45200M | -52.84600M | -91.30900M | -281.56800M | -183.31900M |
| Short term debt | 9.40M | 9.30M | 8.30M | 5.09M | 3.43M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 57.20M | 62.00M | 56.13M | 44.46M | 6.36M |
| Other stockholder equity | 2862.55M | 2770.92M | 2694.65M | 2612.66M | 2402.95M |
| Property plant equipment | - | 61.59M | 66.31M | 9.16M | 3.18M |
| Total current assets | 616.12M | 507.94M | 617.82M | 717.62M | 760.25M |
| Long term investments | - | - | - | - | 2.30M |
| Net tangible assets | - | 400.41M | 540.89M | 625.90M | 696.55M |
| Short term investments | 250.21M | 301.98M | 373.27M | 305.93M | 507.75M |
| Net receivables | 102.35M | 63.08M | 65.34M | 50.28M | 37.87M |
| Long term debt | - | - | - | - | - |
| Inventory | 35.82M | 6.64M | 7.88M | 9.68M | 6.34M |
| Accounts payable | 17.54M | 12.75M | 6.88M | 8.49M | 7.22M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.02M | -0.97500M | -0.19200M | 0.04M | 0.30M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.02M | 0.02M | 0.01M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -2153.57600M | -1985.70600M | -1704.12200M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5.10M | 18.28M | 15.98M | 7.45M | 7.64M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 132.83M | 79.88M | 82.30M | 65.00M | 22.93M |
| Capital lease obligations | 57.20M | 62.00M | 56.13M | 44.46M | 9.79M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 73.24M | -69.98000M | 200.10M | -164.70700M | -69.38500M |
| Change to liabilities | 5.87M | -8.21800M | 31.16M | 12.01M | 11.74M |
| Total cashflows from investing activities | 73.24M | -71.10200M | 192.51M | -165.83600M | -71.48900M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 8.20M | 18.16M | 81.00M | 371.85M | 306.65M |
| Change to operating activities | 27.54M | -2.87800M | 25.55M | 11.08M | 4.24M |
| Net income | -215.97500M | -167.87000M | -281.58400M | -235.25900M | -245.19200M |
| Change in cash | -32.58900M | -178.59300M | 137.33M | 54.88M | 67.69M |
| Begin period cash flow | 153.21M | 331.80M | 194.47M | 139.58M | 71.89M |
| End period cash flow | 120.62M | 153.21M | 331.80M | 194.47M | 139.58M |
| Total cash from operating activities | -114.03500M | -125.66000M | -136.16600M | -151.13000M | -167.47000M |
| Issuance of capital stock | 8.20M | 18.16M | 81.00M | 371.85M | 306.65M |
| Depreciation | 2.03M | 3.34M | 2.93M | 2.77M | 3.00M |
| Other cashflows from investing activities | - | - | - | -164.70700M | 0.04M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 2.42M | -4.21000M | -3.32000M | -1.73700M | 1.93M |
| Change to account receivables | 2.17M | -16.11900M | -12.46600M | -9.69100M | -8.74700M |
| Sale purchase of stock | - | 18.16M | 81.00M | 371.85M | 306.65M |
| Other cashflows from financing activities | 73.24M | -71.10200M | 192.51M | -165.83600M | -71.48900M |
| Change to netincome | 61.92M | 61.29M | 129.98M | 81.27M | 83.49M |
| Capital expenditures | 0.00000M | 1.12M | 7.59M | 1.13M | 2.15M |
| Change receivables | - | -15.06200M | -12.40800M | -10.08500M | -9.35900M |
| Cash flows other operating | - | 2.67M | -4.39500M | 3.52M | -12.50600M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -178.60000M | 137.34M | 54.88M | 67.69M |
| Change in working capital | 37.99M | -24.82400M | 11.04M | 3.71M | -8.19700M |
| Stock based compensation | 68.20M | 63.62M | 84.42M | 82.27M | 81.56M |
| Other non cash items | -6.27800M | 0.07M | 44.28M | -4.60700M | 1.35M |
| Free cash flow | -114.03500M | -126.78200M | -143.75300M | -152.25900M | -169.61800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals Inc |
0.72 4.29% | 17.50 | 23.76 | 26.04 | 3.36 | 5.41 | 2.80 | 20.92 |
| NVO Novo Nordisk A/S |
1.26 1.66% | 77.15 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 76.68 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.85 0.37% | 504.77 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-13.74 2.02% | 666.87 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
12830 El Camino Real, San Diego, CA, United States, 92130
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen R. Davis J.D. | CEO & Director | 1961 |
| Dr. Srdjan R. Stankovic M.D., M.S.P.H. | Pres | 1957 |
| Mr. Mark C. Schneyer | Exec. VP & CFO | 1974 |
| Mr. Brendan P. Teehan | Exec. VP, COO & Head of Commercial | 1969 |
| Mr. Austin D. Kim | Exec. VP, Gen. Counsel & Sec. | 1964 |
| Mr. James K. Kihara | VP, Chief Accounting Officer & Corp. Controller | 1981 |
| Mr. Bob Mischler | Sr. VP of Strategy & Technology Operations | NA |
| Mr. Mark C. Johnson | VP of Investor Relations | NA |
| Ms. Julie Fisher | Sr. VP of Marketing & Commercial Strategy | NA |
| Mr. Rob Ackles | Sr. VP & Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...